The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

SOPHiA GENETICS SA (NASDAQ:SOPH) is one of the

8 Best Healthcare AI Stocks to Buy According to Analysts.

On April 15, 2026, BTIG raised its price target on SOPHiA GENETICS SA (NASDAQ:SOPH) to $8 from $7 and maintained a Buy rating. The firm said management “signaled confidence across the business” following investor meetings with President and incoming CEO Ross Muken, CFO George Cardoza, and Head of Strategy Kellen Sanger.

In March, SOPHiA GENETICS SA (NASDAQ:SOPH) reported Q4 EPS of (28c) compared to (23c) a year earlier, while revenue rose to $21.7 million from $17.7 million. The company said performance was driven by 45% year-over-year growth in North America and 32% growth in the Asia Pacific. CEO Jurgi Camblong said the company finished 2025 with strong momentum, with Q4 revenue up 22% and full-year revenue increasing 19%.

Source: Unsplash

For 2026, SOPHiA GENETICS expects revenue of $92 million to $94 million, above consensus estimates of $76.47 million, representing growth of about 20% to 22% year over year. The company also expects adjusted EBITDA in the range of ($29 million) to ($32 million).

SOPHiA GENETICS SA (NASDAQ:SOPH) provides cloud-based software tools that help healthcare providers analyze complex clinical data and generate insights across multiple diagnostic platforms.

While we acknowledge the potential of SOPH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.